ESAIY News and Press, Eisai Co

Exploring Sleep with Pokemon! Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration TOKYO, Mar 12, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it is launching an initiative to ...

Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting TOKYO, Mar 11, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest finding...

WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) RAHWAY, NJ and TOKYO, Mar 2, 2026 - (JCN Newswire) - Merck & Co.,...

Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy TOKYO, Feb 16, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received an orphan...

Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China TOKYO and CAMBRIDGE, Mass., Feb 10, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo ...

2026-02-09 16:44:19 ET Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call February 9, 2026 3:00 AM EST Company Participants Takuya Oyama - Vice President, Chief Financial Officer & Chief IR Officer Keisuke Naito - Representative Corporate Officer, EVP, COO & Chief Gro...

2026-02-09 06:14:14 ET More on Eisai: Eisai Co., Ltd. 2026 Q3 - Results - Earnings Call Presentation Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiat...

2026-02-06 07:02:19 ET More on Biogen Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma 44th Annual J.P. Morgan Healthcare Conference Biogen Inc. (BIIB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Biogen beats top-l...

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan TOKYO and SHANGHAI, Feb 6, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shang...

FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review TOKYO and CAMBRIDGE, Mass., Jan 26, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters...